Integrated Drug Discovery in Continuous Flow
Abstract There are great opportunities for innovation in the drug discovery process, particularly in the lead development phase. The traditional “design-synthesize-screen” cycle has seen little innovation as a whole despite major advances at each stage, including automated purification and synthesis...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Fleming, Gabrielle S. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Akadémiai Kiadó 2017 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Journal of flow chemistry - [Cham] : Springer International Publishing, 2011, 7(2017), 3-4 vom: Juli, Seite 124-128 |
|---|---|
| Übergeordnetes Werk: |
volume:7 ; year:2017 ; number:3-4 ; month:07 ; pages:124-128 |
| Links: |
|---|
| DOI / URN: |
10.1556/1846.2017.00027 |
|---|
| Katalog-ID: |
SPR038365847 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR038365847 | ||
| 003 | DE-627 | ||
| 005 | 20230519092646.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1556/1846.2017.00027 |2 doi | |
| 035 | |a (DE-627)SPR038365847 | ||
| 035 | |a (SPR)1846.2017.00027-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fleming, Gabrielle S. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Integrated Drug Discovery in Continuous Flow |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Akadémiai Kiadó 2017 | ||
| 520 | |a Abstract There are great opportunities for innovation in the drug discovery process, particularly in the lead development phase. The traditional “design-synthesize-screen” cycle has seen little innovation as a whole despite major advances at each stage, including automated purification and synthesis as well as high throughput biological screening. It could be argued that the hit-to-lead and lead optimization processes remain slow and modular with inefficient flow of information, resulting in a loss of time and money. New flow technologies may provide a promising foundation for developing a continuous integrated small molecule optimization platform that would greatly enhance hit-to-lead and lead optimization programs. Herein, we discuss major developments in integrating synthesis, purification, screening, and machine learning into a single continuous-flow platform and provide some insight into future directions of this field. | ||
| 650 | 4 | |a Drug discovery |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a medicinal chemistry |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a integrated drug discovery |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Beeler, Aaron B. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of flow chemistry |d [Cham] : Springer International Publishing, 2011 |g 7(2017), 3-4 vom: Juli, Seite 124-128 |w (DE-627)77992262X |w (DE-600)2759672-2 |x 2063-0212 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2017 |g number:3-4 |g month:07 |g pages:124-128 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1556/1846.2017.00027 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2190 | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2017 |e 3-4 |c 07 |h 124-128 | ||
| author_variant |
g s f gs gsf a b b ab abb |
|---|---|
| matchkey_str |
article:20630212:2017----::nertdrgicvric |
| hierarchy_sort_str |
2017 |
| publishDate |
2017 |
| allfields |
10.1556/1846.2017.00027 doi (DE-627)SPR038365847 (SPR)1846.2017.00027-e DE-627 ger DE-627 rakwb eng Fleming, Gabrielle S. verfasserin aut Integrated Drug Discovery in Continuous Flow 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Akadémiai Kiadó 2017 Abstract There are great opportunities for innovation in the drug discovery process, particularly in the lead development phase. The traditional “design-synthesize-screen” cycle has seen little innovation as a whole despite major advances at each stage, including automated purification and synthesis as well as high throughput biological screening. It could be argued that the hit-to-lead and lead optimization processes remain slow and modular with inefficient flow of information, resulting in a loss of time and money. New flow technologies may provide a promising foundation for developing a continuous integrated small molecule optimization platform that would greatly enhance hit-to-lead and lead optimization programs. Herein, we discuss major developments in integrating synthesis, purification, screening, and machine learning into a single continuous-flow platform and provide some insight into future directions of this field. Drug discovery (dpeaa)DE-He213 medicinal chemistry (dpeaa)DE-He213 integrated drug discovery (dpeaa)DE-He213 Beeler, Aaron B. aut Enthalten in Journal of flow chemistry [Cham] : Springer International Publishing, 2011 7(2017), 3-4 vom: Juli, Seite 124-128 (DE-627)77992262X (DE-600)2759672-2 2063-0212 nnns volume:7 year:2017 number:3-4 month:07 pages:124-128 https://dx.doi.org/10.1556/1846.2017.00027 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_70 GBV_ILN_702 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_2190 AR 7 2017 3-4 07 124-128 |
| spelling |
10.1556/1846.2017.00027 doi (DE-627)SPR038365847 (SPR)1846.2017.00027-e DE-627 ger DE-627 rakwb eng Fleming, Gabrielle S. verfasserin aut Integrated Drug Discovery in Continuous Flow 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Akadémiai Kiadó 2017 Abstract There are great opportunities for innovation in the drug discovery process, particularly in the lead development phase. The traditional “design-synthesize-screen” cycle has seen little innovation as a whole despite major advances at each stage, including automated purification and synthesis as well as high throughput biological screening. It could be argued that the hit-to-lead and lead optimization processes remain slow and modular with inefficient flow of information, resulting in a loss of time and money. New flow technologies may provide a promising foundation for developing a continuous integrated small molecule optimization platform that would greatly enhance hit-to-lead and lead optimization programs. Herein, we discuss major developments in integrating synthesis, purification, screening, and machine learning into a single continuous-flow platform and provide some insight into future directions of this field. Drug discovery (dpeaa)DE-He213 medicinal chemistry (dpeaa)DE-He213 integrated drug discovery (dpeaa)DE-He213 Beeler, Aaron B. aut Enthalten in Journal of flow chemistry [Cham] : Springer International Publishing, 2011 7(2017), 3-4 vom: Juli, Seite 124-128 (DE-627)77992262X (DE-600)2759672-2 2063-0212 nnns volume:7 year:2017 number:3-4 month:07 pages:124-128 https://dx.doi.org/10.1556/1846.2017.00027 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_70 GBV_ILN_702 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_2190 AR 7 2017 3-4 07 124-128 |
| allfields_unstemmed |
10.1556/1846.2017.00027 doi (DE-627)SPR038365847 (SPR)1846.2017.00027-e DE-627 ger DE-627 rakwb eng Fleming, Gabrielle S. verfasserin aut Integrated Drug Discovery in Continuous Flow 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Akadémiai Kiadó 2017 Abstract There are great opportunities for innovation in the drug discovery process, particularly in the lead development phase. The traditional “design-synthesize-screen” cycle has seen little innovation as a whole despite major advances at each stage, including automated purification and synthesis as well as high throughput biological screening. It could be argued that the hit-to-lead and lead optimization processes remain slow and modular with inefficient flow of information, resulting in a loss of time and money. New flow technologies may provide a promising foundation for developing a continuous integrated small molecule optimization platform that would greatly enhance hit-to-lead and lead optimization programs. Herein, we discuss major developments in integrating synthesis, purification, screening, and machine learning into a single continuous-flow platform and provide some insight into future directions of this field. Drug discovery (dpeaa)DE-He213 medicinal chemistry (dpeaa)DE-He213 integrated drug discovery (dpeaa)DE-He213 Beeler, Aaron B. aut Enthalten in Journal of flow chemistry [Cham] : Springer International Publishing, 2011 7(2017), 3-4 vom: Juli, Seite 124-128 (DE-627)77992262X (DE-600)2759672-2 2063-0212 nnns volume:7 year:2017 number:3-4 month:07 pages:124-128 https://dx.doi.org/10.1556/1846.2017.00027 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_70 GBV_ILN_702 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_2190 AR 7 2017 3-4 07 124-128 |
| allfieldsGer |
10.1556/1846.2017.00027 doi (DE-627)SPR038365847 (SPR)1846.2017.00027-e DE-627 ger DE-627 rakwb eng Fleming, Gabrielle S. verfasserin aut Integrated Drug Discovery in Continuous Flow 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Akadémiai Kiadó 2017 Abstract There are great opportunities for innovation in the drug discovery process, particularly in the lead development phase. The traditional “design-synthesize-screen” cycle has seen little innovation as a whole despite major advances at each stage, including automated purification and synthesis as well as high throughput biological screening. It could be argued that the hit-to-lead and lead optimization processes remain slow and modular with inefficient flow of information, resulting in a loss of time and money. New flow technologies may provide a promising foundation for developing a continuous integrated small molecule optimization platform that would greatly enhance hit-to-lead and lead optimization programs. Herein, we discuss major developments in integrating synthesis, purification, screening, and machine learning into a single continuous-flow platform and provide some insight into future directions of this field. Drug discovery (dpeaa)DE-He213 medicinal chemistry (dpeaa)DE-He213 integrated drug discovery (dpeaa)DE-He213 Beeler, Aaron B. aut Enthalten in Journal of flow chemistry [Cham] : Springer International Publishing, 2011 7(2017), 3-4 vom: Juli, Seite 124-128 (DE-627)77992262X (DE-600)2759672-2 2063-0212 nnns volume:7 year:2017 number:3-4 month:07 pages:124-128 https://dx.doi.org/10.1556/1846.2017.00027 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_70 GBV_ILN_702 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_2190 AR 7 2017 3-4 07 124-128 |
| allfieldsSound |
10.1556/1846.2017.00027 doi (DE-627)SPR038365847 (SPR)1846.2017.00027-e DE-627 ger DE-627 rakwb eng Fleming, Gabrielle S. verfasserin aut Integrated Drug Discovery in Continuous Flow 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Akadémiai Kiadó 2017 Abstract There are great opportunities for innovation in the drug discovery process, particularly in the lead development phase. The traditional “design-synthesize-screen” cycle has seen little innovation as a whole despite major advances at each stage, including automated purification and synthesis as well as high throughput biological screening. It could be argued that the hit-to-lead and lead optimization processes remain slow and modular with inefficient flow of information, resulting in a loss of time and money. New flow technologies may provide a promising foundation for developing a continuous integrated small molecule optimization platform that would greatly enhance hit-to-lead and lead optimization programs. Herein, we discuss major developments in integrating synthesis, purification, screening, and machine learning into a single continuous-flow platform and provide some insight into future directions of this field. Drug discovery (dpeaa)DE-He213 medicinal chemistry (dpeaa)DE-He213 integrated drug discovery (dpeaa)DE-He213 Beeler, Aaron B. aut Enthalten in Journal of flow chemistry [Cham] : Springer International Publishing, 2011 7(2017), 3-4 vom: Juli, Seite 124-128 (DE-627)77992262X (DE-600)2759672-2 2063-0212 nnns volume:7 year:2017 number:3-4 month:07 pages:124-128 https://dx.doi.org/10.1556/1846.2017.00027 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_70 GBV_ILN_702 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_2190 AR 7 2017 3-4 07 124-128 |
| language |
English |
| source |
Enthalten in Journal of flow chemistry 7(2017), 3-4 vom: Juli, Seite 124-128 volume:7 year:2017 number:3-4 month:07 pages:124-128 |
| sourceStr |
Enthalten in Journal of flow chemistry 7(2017), 3-4 vom: Juli, Seite 124-128 volume:7 year:2017 number:3-4 month:07 pages:124-128 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Drug discovery medicinal chemistry integrated drug discovery |
| isfreeaccess_bool |
true |
| container_title |
Journal of flow chemistry |
| authorswithroles_txt_mv |
Fleming, Gabrielle S. @@aut@@ Beeler, Aaron B. @@aut@@ |
| publishDateDaySort_date |
2017-07-01T00:00:00Z |
| hierarchy_top_id |
77992262X |
| id |
SPR038365847 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR038365847</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519092646.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1556/1846.2017.00027</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR038365847</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)1846.2017.00027-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fleming, Gabrielle S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Integrated Drug Discovery in Continuous Flow</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Akadémiai Kiadó 2017</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract There are great opportunities for innovation in the drug discovery process, particularly in the lead development phase. The traditional “design-synthesize-screen” cycle has seen little innovation as a whole despite major advances at each stage, including automated purification and synthesis as well as high throughput biological screening. It could be argued that the hit-to-lead and lead optimization processes remain slow and modular with inefficient flow of information, resulting in a loss of time and money. New flow technologies may provide a promising foundation for developing a continuous integrated small molecule optimization platform that would greatly enhance hit-to-lead and lead optimization programs. Herein, we discuss major developments in integrating synthesis, purification, screening, and machine learning into a single continuous-flow platform and provide some insight into future directions of this field.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug discovery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">medicinal chemistry</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">integrated drug discovery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Beeler, Aaron B.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of flow chemistry</subfield><subfield code="d">[Cham] : Springer International Publishing, 2011</subfield><subfield code="g">7(2017), 3-4 vom: Juli, Seite 124-128</subfield><subfield code="w">(DE-627)77992262X</subfield><subfield code="w">(DE-600)2759672-2</subfield><subfield code="x">2063-0212</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:3-4</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:124-128</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1556/1846.2017.00027</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2017</subfield><subfield code="e">3-4</subfield><subfield code="c">07</subfield><subfield code="h">124-128</subfield></datafield></record></collection>
|
| author |
Fleming, Gabrielle S. |
| spellingShingle |
Fleming, Gabrielle S. misc Drug discovery misc medicinal chemistry misc integrated drug discovery Integrated Drug Discovery in Continuous Flow |
| authorStr |
Fleming, Gabrielle S. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)77992262X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2063-0212 |
| topic_title |
Integrated Drug Discovery in Continuous Flow Drug discovery (dpeaa)DE-He213 medicinal chemistry (dpeaa)DE-He213 integrated drug discovery (dpeaa)DE-He213 |
| topic |
misc Drug discovery misc medicinal chemistry misc integrated drug discovery |
| topic_unstemmed |
misc Drug discovery misc medicinal chemistry misc integrated drug discovery |
| topic_browse |
misc Drug discovery misc medicinal chemistry misc integrated drug discovery |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of flow chemistry |
| hierarchy_parent_id |
77992262X |
| hierarchy_top_title |
Journal of flow chemistry |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)77992262X (DE-600)2759672-2 |
| title |
Integrated Drug Discovery in Continuous Flow |
| ctrlnum |
(DE-627)SPR038365847 (SPR)1846.2017.00027-e |
| title_full |
Integrated Drug Discovery in Continuous Flow |
| author_sort |
Fleming, Gabrielle S. |
| journal |
Journal of flow chemistry |
| journalStr |
Journal of flow chemistry |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
txt |
| container_start_page |
124 |
| author_browse |
Fleming, Gabrielle S. Beeler, Aaron B. |
| container_volume |
7 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Fleming, Gabrielle S. |
| doi_str_mv |
10.1556/1846.2017.00027 |
| title_sort |
integrated drug discovery in continuous flow |
| title_auth |
Integrated Drug Discovery in Continuous Flow |
| abstract |
Abstract There are great opportunities for innovation in the drug discovery process, particularly in the lead development phase. The traditional “design-synthesize-screen” cycle has seen little innovation as a whole despite major advances at each stage, including automated purification and synthesis as well as high throughput biological screening. It could be argued that the hit-to-lead and lead optimization processes remain slow and modular with inefficient flow of information, resulting in a loss of time and money. New flow technologies may provide a promising foundation for developing a continuous integrated small molecule optimization platform that would greatly enhance hit-to-lead and lead optimization programs. Herein, we discuss major developments in integrating synthesis, purification, screening, and machine learning into a single continuous-flow platform and provide some insight into future directions of this field. © Akadémiai Kiadó 2017 |
| abstractGer |
Abstract There are great opportunities for innovation in the drug discovery process, particularly in the lead development phase. The traditional “design-synthesize-screen” cycle has seen little innovation as a whole despite major advances at each stage, including automated purification and synthesis as well as high throughput biological screening. It could be argued that the hit-to-lead and lead optimization processes remain slow and modular with inefficient flow of information, resulting in a loss of time and money. New flow technologies may provide a promising foundation for developing a continuous integrated small molecule optimization platform that would greatly enhance hit-to-lead and lead optimization programs. Herein, we discuss major developments in integrating synthesis, purification, screening, and machine learning into a single continuous-flow platform and provide some insight into future directions of this field. © Akadémiai Kiadó 2017 |
| abstract_unstemmed |
Abstract There are great opportunities for innovation in the drug discovery process, particularly in the lead development phase. The traditional “design-synthesize-screen” cycle has seen little innovation as a whole despite major advances at each stage, including automated purification and synthesis as well as high throughput biological screening. It could be argued that the hit-to-lead and lead optimization processes remain slow and modular with inefficient flow of information, resulting in a loss of time and money. New flow technologies may provide a promising foundation for developing a continuous integrated small molecule optimization platform that would greatly enhance hit-to-lead and lead optimization programs. Herein, we discuss major developments in integrating synthesis, purification, screening, and machine learning into a single continuous-flow platform and provide some insight into future directions of this field. © Akadémiai Kiadó 2017 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_70 GBV_ILN_702 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_2190 |
| container_issue |
3-4 |
| title_short |
Integrated Drug Discovery in Continuous Flow |
| url |
https://dx.doi.org/10.1556/1846.2017.00027 |
| remote_bool |
true |
| author2 |
Beeler, Aaron B. |
| author2Str |
Beeler, Aaron B. |
| ppnlink |
77992262X |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1556/1846.2017.00027 |
| up_date |
2024-07-03T17:38:37.213Z |
| _version_ |
1803580412750987264 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR038365847</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519092646.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1556/1846.2017.00027</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR038365847</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)1846.2017.00027-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fleming, Gabrielle S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Integrated Drug Discovery in Continuous Flow</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Akadémiai Kiadó 2017</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract There are great opportunities for innovation in the drug discovery process, particularly in the lead development phase. The traditional “design-synthesize-screen” cycle has seen little innovation as a whole despite major advances at each stage, including automated purification and synthesis as well as high throughput biological screening. It could be argued that the hit-to-lead and lead optimization processes remain slow and modular with inefficient flow of information, resulting in a loss of time and money. New flow technologies may provide a promising foundation for developing a continuous integrated small molecule optimization platform that would greatly enhance hit-to-lead and lead optimization programs. Herein, we discuss major developments in integrating synthesis, purification, screening, and machine learning into a single continuous-flow platform and provide some insight into future directions of this field.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug discovery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">medicinal chemistry</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">integrated drug discovery</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Beeler, Aaron B.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of flow chemistry</subfield><subfield code="d">[Cham] : Springer International Publishing, 2011</subfield><subfield code="g">7(2017), 3-4 vom: Juli, Seite 124-128</subfield><subfield code="w">(DE-627)77992262X</subfield><subfield code="w">(DE-600)2759672-2</subfield><subfield code="x">2063-0212</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:3-4</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:124-128</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1556/1846.2017.00027</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2017</subfield><subfield code="e">3-4</subfield><subfield code="c">07</subfield><subfield code="h">124-128</subfield></datafield></record></collection>
|
| score |
7.398202 |